Filter
520
Text search:
Xpert
Featured
79
117
Language
Document type
316
85
50
27
15
14
9
2
1
1
Countries
27
24
19
16
15
10
9
9
8
8
7
7
7
6
6
6
5
5
5
5
5
5
5
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
170
76
14
8
7
3
1
Toolboxes
338
31
29
11
7
7
6
5
5
4
2
1
1
1
1
1
Background paper 7
The Independent Panel for Pandemic Preparedness and Response
May 2021
In 2019, an estimated 10 million individuals fell ill with tuberculosis (TB) and 3 million of them were not reported to have beendiagnosed and notified. The gap is proportionately even wider for drug-resistant TB. Of the estimated 465 000 patients with rifampicin-resistant and multi-drug resistant T
...
Guia rápido para profissionais de saúde
he WHO South-East Region in 2019 accounted for nearly a million missing TB patients from the estimated incidence. Active case-finding (ACF) or systematic screening for tuberculosis is an important tool to reach out to missing TB patients. When appropriately implemented, the activity is cost effectiv
...
Tuberculosis (TB) is the leading cause of death from a single infectious agent even if is largely curable and
preventable. In 2019 an estimated 2.9 million of the 10 million people who fell ill with TB were not
diagnosed or reported to the World Health Organization1. The Politi
...
This rapid communication outlines the main outcomes of a WHO convened Guideline Development Group (GDG) meeting, held in May-June 2021 on the topic of the management of TB in children and adolescents. The rapid communication aims to inform staff from ministries of health and care providers across p
...
The Compendium of data and evidence-related tools for use in TB planning and programming was developed as a companion document to the People-centred framework for tuberculosis programme planning and prioritization – user guide, published by the World Health Organization (WHO)
...
La publicación describe los procedimientos estandarizados para la atención integral de las personas diagnosticadas con tuberculosis y Virus de Inmunodeficiencia Humana en los servicios de salud a nivel nacional, así como los procesos de atención integral en las personas diagnosticadas con tuberc
...
OBJETIVO DE LA GUÍA
Describir los lineamientos técnicos de la vigilancia de tuberculosis por el laboratorio, así como los
procesos de obtención, recolección, procesamiento, transporte y conservación de muestras, y las
funciones que se realizan y articulan por todos los integra
...
COVID-19 Management Guide -Version June 2021
Following review of evidence and advice from the Technical Advisory Group (TAG) on Tuberculosis (TB) Diagnostics and Laboratory Strengthening, the World Health Organization (WHO) announces that current WHO recommendations for the use of interferon-gamma release assays (IGRA) are also valid for Beij
...
This guidance provides interim guidance for the integration of SARS-CoV-2 and influenza virologic and genomic surveillance, from sentinel site case enrolment and sampling to the eventual sharing of the virus sequence data, a process known as end-to-end surveillance. This guidance builds on experienc
...
WHO Information Leaflet COVID-19: Considerations on tuberculosis (TB) care
Laboratory Safety Handbook. Global edition
Las pruebas de cultivo y sensibilidad a fármacos son necesarias especialmente para los pacientes con riesgo de tuberculosis resistente a los medicamentos y para vigilar su respuesta al tratamiento. Si bien el cultivo y las pruebas de sensibilidad son ca
...
The Ideal Clinic Realisation and Maintenance (ICRM) programme was initiated by the National Department of Health in July 2013 in order to systematically improve primary health care (PHC) facilities and the quality of care they provide. The Ideal Clinic framework/dashboard sets out the standards for
...
Estas directrices sustituyen a los anteriores documentos de política de la OMS sobre el manejo de la ILTB en las personas con la infección por el VIH, los contactos del hogar de personas con TB y otros grupos de riesgo. Las Directrices unificadas de la OMS sobre la tuberculosis: Tratamiento preven
...
The results of the SHINE trial have been published in the NEJM today. SHINE looked at whether treatment for children with minimal TB could be reduced from 6 months to 4 months. It found that the four month treatment was as good as the standard six months treatment for children with minimal TB
N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535
Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative tuberculosis (SHINE Study)
